Development of oral osteomucosal tissue constructs in vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue

International Journal of Molecular Medicine

Volumn 34, Issue 2, 2014, Pages 559-563

  Bae, Susan ^a   Sun, Shuting ^b   Aghaloo, Tara ^a   Oh, Ju Eun ^a   McKenna, Charles E ^b   Kang, Mo K ^a,c   Shin, Ki Hyuk ^a,c   Tetradis, Sotirios ^a   Park, No Hee ^a,c,d   Kim, Reuben H ^a,c  

^a UCLA SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Kyung Hee University   (South Korea)

Author keywords

Bisphosphonates; Hard tissue; Osteomucosal tissue constructs; Osteonecrosis of the jaw; Soft tissue; Toxicity; Ulceration

Indexed keywords

AF 647; BISPHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BONE; CYTOTOXICITY; EPITHELIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUTH CAVITY; OSTEOCYTE; PERIOSTEUM; PRIORITY JOURNAL; SOFT TISSUE; ANIMAL; CELL DIFFERENTIATION; DRUG EFFECTS; DRUG THERAPY; METABOLISM; MOUTH MUCOSA; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; RAT;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; DIPHOSPHONATES; IN VITRO TECHNIQUES; MOUTH MUCOSA; OSTEOCLASTS; OSTEOCYTES; RATS;

EID: 84904244955     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1802     Document Type: Article

References (41)

1. Black DM, Delmas PD, Eastell R, et al: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822, 2007. (Pubitemid 46698462)
2. Lyles KW, Colon-Emeric CS, Magaziner JS, et al: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799-1809, 2007. (Pubitemid 350044800)
3. Healy JH and Brown HK: Complications of bone metastases: surgical management. Cancer 88: 2940-2951, 2000.
4. Brufsky AM: Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 13: 187-195, 2008.
5. Abrahamsen B: Adverse effects of bisphosphonates. Calcif Tissue Int 86: 421-435, 2010.
6. Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11: 491-498, 1993. (Pubitemid 23071047)
7. De Groen PC, Lubbe DF, Hirsch LJ, et al: Esophagitis associated with the use of alendronate. N Engl J Med 335: 1016-1021, 1996. (Pubitemid 26338731)
8. Rubegni P and Fimiani M: Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med 355: e25, 2006. (Pubitemid 44837775)
9. Reid IR and Cornish J: Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 8: 90-96, 2011.
10. Ruggiero SL, Dodson TB, Assael LA, et al: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67: 2-12, 2009.
11. Kim RH, Lee RS, Williams D, et al: Bisphosphonates induce senescence in normal human oral keratinocytes. J Dent Res 90: 810-816, 2011.
12. Van den Wyngaert T, Huizing MT and Vermorken JB: Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17: 1197-1204, 2006. (Pubitemid 44288209)
13. Levin L, Laviv A and Schwartz-Arad D: Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 138: 1218-1220, 2007.
14. Goldman ML, Denduluri N, Berman AW, et al: A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology 71: 306-308, 2006.
15. Roelofs, AJ, Coxon FP, Ebetino FH, et al: Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25: 606-616, 2010.
16. Roelofs, AJ, Stewart CA, Sun S, et al: Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 27: 835-847, 2012.
17. Park NH, Min BM, Li SL, et al: Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis 12: 1627-1631, 1991.
18. Sun S, Błażewska KM, Kashemirov BA, et al: Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. Phosphorus Sulfur Silicon Relat Elem 186: 970-971, 2011.
19. Klausner M, Ayehunie S, Breyfogle BA, et al: Organotypic human oral tissue models for toxicological studies. Toxicol In Vitro 21: 938-949, 2007. (Pubitemid 46603236)
20. Garlick JA, Parks WC, Welgus HG and Taichman LB: Re-epithelialization of human oral keratinocytes in vitro. J Dent Res 75: 912-918, 1996. (Pubitemid 32763600)
21. Andrei G, Duraffour S, Van den Oord J and Snoeck R: Epithelial raft cultures for investigations of virus growth, pathogenesis and efficacy of antiviral agents. Antiviral Res 85: 431-449, 2010.
22. Liu J, Bian Z, Kuijpers-Jagtman AM and Von den Hoff JW: Skin and oral mucosa equivalents: construction and performance. Orthod Craniofac Res 13: 11-20, 2010.
23. Kim RH, Mehrazarin S and Kang MK: Therapeutic potential of mesenchymal stem cells for oral and systemic diseases. Dent Clin North Am 56: 651-675, 2012.
24. Coxon FP, Thompson K and Rogers MJ: Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6: 307-312, 2006. (Pubitemid 43670914)
25. Brenner AI, Koshy J, Morey J, et al: The bone scan. Semin Nucl Med 42: 11-26, 2012.
26. Peller PJ, Ho VB and Kransdorf MJ: Extraosseous Tc-99m MDP uptake: a pathophysiologic approach. Radiographics 13: 715-734, 1993.
27. Proksch E, Brandner JM and Jensen JM: The skin: an indispensable barrier. Exp Dermatol 17: 1063-1072, 2008.
28. Rogers MJ, Crockett JC, Coxon FP, et al: Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49: 34-41, 2011.
29. van Beek E, Pieterman E, Cohen L, et al: Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255: 491-494, 1999. (Pubitemid 29292287)
30. Luckman SP, Hughes DE, Coxon FP, et al: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589, 1998. (Pubitemid 28163009)
31. Senaratne SG, Pirianov G, Mansi JL, et al: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000. (Pubitemid 30175914)
32. Goffinet M, Thoulouzan M, Pradines A, et al: Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6: 60, 2006.
33. Ory B, Moriceau G, Trichet V, et al: Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2: 928-941, 2008. (Pubitemid 351718071)
34. Elias PM: Stratum corneum defensive functions: an integrated view. J Invest Dermatol 125: 183-200, 2005.
35. Suri S, Monkkonen J, Taskinen M, et al: Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29: 336-343, 2001. (Pubitemid 32930060)
36. Pazianas M and Abrahamsen B: Safety of bisphosphonates. Bone 49: 103-110, 2011.
37. van Staa T, Abenhaim L and Cooper C: Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 103: 462-467, 1997. (Pubitemid 28018647)
38. Graham DY: What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 47: 1665-1678, 2002.
39. Landesberg R, Cozin M, Cremers S, et al: Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66: 839-847, 2008. (Pubitemid 351522817)
40. Scheper MA, Badros A, Chaisuparat R, et al: Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144: 667-676, 2009.
41. Arai N, Inoue S, Tomihara K, et al: In vitro synergistic effects of zoledronic acid and calcium on viability of human epithelial cells. Oral Dis 19: 200-205, 2012.